Cross-sectional study assesses lower muscle mass and its correlation with serum phosphorus in T2DM patients, suggesting potential health impacts.
This study aimed to evaluate the correlation between serum phosphorus level and low muscle mass in patients with type 2 diabetes mellitus (T2DM). In this cross-sectional study, 1078 T2DM inpatients were recruited. Low muscle mass was defined as a skeletal muscle index (SMI) < 7.0 kg/m 2 for men and < 5.4 kg/m 2 for women, which measured by dual-energy X-ray absorptiometry. Serum phosphorus (P) was measured using the phosphomolybdate method. Clinical information and other biochemical characteristics were measured and recorded. The prevalence of low muscle mass was 20.2% in men and 13.6% in women. A higher serum phosphorus level was associated with a significantly lower risk of low muscle mass in both genders after multivariable adjustment. A nonlinear, threshold-dependent positive correlation was observed between serum phosphorus and SMI, with significant associations below cohort-specific thresholds of 0.98 mmol/L in men and 1.04 mmol/L in women. Higher serum phosphorus level is associated with a lower prevalence of low muscle mass (i.e., positively correlated with SMI) in T2DM patients. And this exploratory finding requires validation in longitudinal studies.
No takes yet. Share an insight, caveat, or question.
Gao et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: